Anticancer activity of polyoxomolybdate

• Published in: Biomedicine & pharmacotherapy Vol. 60; no. 7; pp. 349 - 352
• Main Authors: Yanagie, H., Ogata, A., Mitsui, S., Hisa, T., Yamase, T., Eriguchi, M.
• Format: Journal Article
• Language: English
• Published: Paris Elsevier SAS 01.08.2006; Elsevier
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Apoptosis; Biological and medical sciences; Cancer growth inhibition; Humans; Medical sciences; Molybdenum - chemistry; Molybdenum - therapeutic use; Neoplasms - drug therapy; Oxides - chemistry; Oxides - therapeutic use; Pharmacology. Drug treatments; Polyoxomolybdate; Redox reaction; Polyoxomolybdate; Cancer growth inhibition; Apoptosis; Redox reaction; Antineoplastic agent; Growth; Cell death; Inhibitor; Inhibition; Malignant tumor; Biological activity; Cancer
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2006.06.018

Anticancer polyoxomolybdates have been investigated for medical application of polyoxometalates as discrete cluster anions of metal oxides. [NH 3Pr i] 6[Mo 7O 24]·3H 2O (PM-8) has been recognized as one of significant antitumoral polyoxomolybdates. PM-8 had shown the growth suppression against several tumors, for examples, Co-4, human colon cancer, MX-1, human breast cancer, and OAT, human lung cancer. PM-8 showed the tumor growth suppression for MKN-45 human gastric cancer in tumor bearing mice. PM-8 inhibited the cell growth of AsPC-1 which depended on the dose with showing DNA ladder formation and DNA fragmentation, and positive Hoechst staining indicating apoptosis. The ratio of apoptotic cells on flow cytometry analysis were 35%, and 57% with treatment of PM-8 after 48, and 72 h, respectively. One of the anti-tumor activity of PM-8 result from the activation of apoptotic pathway. It is thought that polyoxomolybdates will be applied as a novel anti-tumor agent especially against cancers which are difficult to be treated clinically.